- Home
- GILD vs MDT Comparison
GILD vs MDT Comparison
Compare GILD & MDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- MDT
- Stock Information
- Founded
- GILD 1987
- MDT 1949
- Country
- GILD United States
- MDT Ireland
- Employees
- GILD N/A
- MDT N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- MDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- GILD Health Care
- MDT Health Care
- Exchange
- GILD Nasdaq
- MDT Nasdaq
- Market Cap
- GILD 129.9B
- MDT 112.1B
- IPO Year
- GILD 1992
- MDT N/A
- Fundamental
- Price
- GILD $109.11
- MDT $86.35
- Analyst Decision
- GILD Buy
- MDT Buy
- Analyst Count
- GILD 25
- MDT 15
- Target Price
- GILD $110.17
- MDT $98.00
- AVG Volume (30 Days)
- GILD 7.8M
- MDT 8.8M
- Earning Date
- GILD 08-07-2025
- MDT 05-21-2025
- Dividend Yield
- GILD 2.93%
- MDT 3.31%
- EPS Growth
- GILD 1118.07
- MDT 30.80
- EPS
- GILD 4.73
- MDT 3.61
- Revenue
- GILD $28,735,000,000.00
- MDT $33,537,000,000.00
- Revenue This Year
- GILD $1.55
- MDT $6.31
- Revenue Next Year
- GILD $3.69
- MDT $5.27
- P/E Ratio
- GILD $22.83
- MDT $23.75
- Revenue Growth
- GILD 4.68
- MDT 3.62
- 52 Week Low
- GILD $62.69
- MDT $75.96
- 52 Week High
- GILD $119.96
- MDT $96.25
- Technical
- Relative Strength Index (RSI)
- GILD 49.92
- MDT 50.88
- Support Level
- GILD $107.19
- MDT $85.41
- Resistance Level
- GILD $111.78
- MDT $88.77
- Average True Range (ATR)
- GILD 2.77
- MDT 1.27
- MACD
- GILD -0.44
- MDT -0.02
- Stochastic Oscillator
- GILD 33.91
- MDT 56.86
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About MDT Medtronic plc.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.